Inclacumab ELISA Kit,96T,DB885028-96T,Abinscience

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD62P has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Inclacumab in the sample competitively binds to the pre-coated protein with biotin-labeled Inclacumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Inclacumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Stability and Storage	When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
Detection method	Colorimetric
Sample type	Plasma, Serum
Assay type	Quantitative
Sensitivity	5.67 ng/mL
Range	31.25 - 2,000 ng/mL
Recovery	80-120%
Background	Inclacumab is an IgG4 type human monoclonal antibody that inhibits P-selectin, which functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. This drug was developed by Genentech/Roche to reduce the inflammation and heart tissue damage that often occurs during heart surgery when opening up clogged arteries. Global Blood Therapeutics is licensed the drug and plants to investigate the effects of the drug on the vaso-occlusive crisis, a painful complication of sickle cell disease as a complement to its lead investigational oral, voxelotor.
Alternative Names	LC1004-002, RO4905417, CAS: 1256258-86-2
Shipping	2-8 ℃
Specifications	Inclacumab
Note	For Research Use Only.